Drug Profile
Research programme: DNA-based recombinant proteins - GeneOne Life Science
Alternative Names: Adiponectin; Factor VIII; FNDC5Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator GeneOne Life Science
- Developer GeneOne Life Science; Yonsei University Health System
- Class Antihaemorrhagics; Antineoplastics; DNA; Obesity therapies; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Haemophilia; Metabolic disorders; Obesity
Most Recent Events
- 04 Sep 2023 Preclinical development is ongoing in Cancer in South Korea (Parenteral, Injection) (GeneOne Life Science pipeline; September 2023)
- 04 Sep 2023 Preclinical development is ongoing in Haemophilia in South Korea (Parenteral, Injection) (GeneOne Life Science pipeline; September 2023)
- 04 Sep 2023 Preclinical development is ongoing in Metabolic-disorders in South Korea (Parenteral, Injection) (GeneOne Life Science pipeline; September 2023)